A digital remote olfactory assessment test, AROMHA Brain Health Test, was developed by researchers at Massachusetts General Hospital to screen preclinical Alzheimer's disease and neurocognitive disorders.

It differentiated between cognitively normal older adults and those with mild cognitive impairment, detecting age-related olfactory decline. Olfactory performance is associated with AD biomarkers, making olfactory testing a potential early screening approach. The test components include odor percept identification, odor episodic memory, odor discrimination, and metacognition measure. The test has potential applications in efficient screening for clinical trials targeting preclinical or early-stage disease and in exploring the utility of olfactory biomarkers to predict neurodegenerative diseases.

Source: Scientific Reports